Healthtech startup Tvaster Genkalp has raised $1.25 million in its pre-Series A round, led by Ideaspring Capital. Existing investors, including Invigo Softwares and renowned liver transplant specialist Prof. Mohamed Rela, also participated in the funding.
The capital infusion will support the expansion and marketing of Episcreen™ Liver, an innovative blood test designed for early liver cancer detection. With a remarkable 90% accuracy rate, Episcreen™ Liver significantly outperforms the current standard, Alpha-Fetoprotein (AFP), which has a sensitivity of just 50%.
Founded in 2021 by Dr. Srikar Raman and K. Sreedurgalakshmi, Tvaster Genkalp is dedicated to developing high-accuracy, non-invasive cancer diagnostics. The startup aims to revolutionize early cancer detection and treatment, particularly for liver cancer, which affects over 900,000 people worldwide annually.
To date, Tvaster has tested Episcreen™ Liver on over 600 patients and is actively seeking partnerships with leading diagnostic laboratories to enhance accessibility. Beyond liver cancer, the company is also researching diagnostic solutions for bile duct cancer and treatment resistance in childhood liver cancer.
Tvaster Genkalp’s contributions to cancer diagnostics have been widely recognized. The startup recently received the ILTS Young Researcher Award and secured a BIRAC BIG Grant to further its innovations in the field.
With this fresh round of funding, Tvaster is poised to transform liver cancer detection and improve patient outcomes on a global scale.
